Search

Displaying results 1811 - 1820 of 8468 in total
  1. Drug

    Phenylalanine

    go.drugbank.com/drugs/DB00120
    ApprovedInvestigationalNutraceutical

    Phenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.

    Mixtures: LEVAMIN PAD, EAS ORAL 100 TABLET
  2. Drug

    Oxiconazole

    go.drugbank.com/drugs/DB00239
    Approved

    It is marketed under the brand names Oxistat and Oxistat, and is used in the treatment of various skin infections such as athlete's foot, jock itch and ringworm.

  3. Drug

    Chlorphenesin

    go.drugbank.com/drugs/DB00856
    Approved

  4. Drug

    Acrivastine

    go.drugbank.com/drugs/DB09488
    Approved

    As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension … Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D.

  5. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

  6. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    [A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. … [A198771,A198777,A193800] Camostat mesylate was first approved in Japan in January 2006.[L13197]

  7. Drug

    Oxilofrine

    go.drugbank.com/drugs/DB11610
    Approved

    Oxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

  8. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. … [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.

  9. Drug

    Colfosceril palmitate

    go.drugbank.com/drugs/DB09114
    ApprovedWithdrawn

    [A31510] It was part of the first generation of commercially available artificial surfactants.[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.

  10. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [L42330] LetibotulinumtoxinA has been a market-leading cosmetic product in South Korea for a number of years and was subsequently approved in the European Union. … [A249920] The first aesthetic use of botulinum toxin was reported in 1989, when [onabotulinumtoxinA] (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial nerve damage.